MARKET

VTYX

VTYX

Ventyx Biosciences, Inc.
NASDAQ
7.74
+0.05
+0.65%
After Hours: 7.77 +0.03 +0.39% 18:23 12/18 EST
OPEN
7.76
PREV CLOSE
7.69
HIGH
7.95
LOW
7.59
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
10.55
52 WEEK LOW
0.7830
MARKET CAP
552.32M
P/E (TTM)
-5.1621
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VTYX last week (1208-1212)?
Weekly Report · 3d ago
Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)
TipRanks · 12/09 11:57
Weekly Report: what happened at VTYX last week (1201-1205)?
Weekly Report · 12/08 09:41
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/04 21:05
Wells Fargo Remains a Buy on Ventyx Biosciences (VTYX)
TipRanks · 12/03 12:48
Ventyx Biosciences: Strategic Adjustments and Expert Appointments Justify Buy Rating
TipRanks · 12/02 17:15
Promising Developments in Ventyx Biosciences’ Clinical Trials Support Buy Rating
TipRanks · 12/02 17:15
Ventyx Biosciences appoints Mark McKenna as strategic advisor
TipRanks · 12/02 12:11
More
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

Webull offers Ventyx Biosciences Inc stock information, including NASDAQ: VTYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTYX stock methods without spending real money on the virtual paper trading platform.